Pneumonia | PK Analysis of Moxifloxacin in the Treatment of CAP
Pneumonia research study
What is the primary objective of this study?
At the Department of Infectious Diseases, Aarhus Denmark, moxifloxacin is used in the empirical treatment of severe community-acquired pneumonia (CAP). This study was designed to determine the pharmacokinetics of moxifloxacin 400 mg/day to patients treated empirically for CAP. To accomplish this aim, we established a pharmacokinetic population model. This approach was adopted with the dual purpose of assessing the potential efficacy of the drug and performing Monte-Carlo simulations to characterize the maximal MICs for which recommended pharmacokinetic-pharmacodynamic (PK-PD) targets are obtained for pathogens commonly known to cause CAP.
Who is eligible to participate?
Inclusion Criteria: - Patients with community-acquired pneumonia, treated with moxifloxacin Exclusion Criteria: - Under 18 years of age
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Pharmacokinetics MoxifloxacinPatients with community-acquired pneumonia treated with moxifloxacin
Start Date: April 2013
Completed Date: October 2014
Primary Outcome: Total Peak Plasma Concentration (Cmax)
Study sponsors, principal investigator, and references
Principal Investigator: Eskild Petersen, MD, Assoc. Prof., D.Sc.
Lead Sponsor: University of Aarhus